Literature DB >> 17600544

Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors.

Fu-Ming Shen1, Jin Wang, Can-Rong Ni, Jian-Guang Yu, Wei-Zhong Wang, Ding-Feng Su.   

Abstract

1. Ketanserin may influence baroreflex function by blocking 5-HT(2A) receptors and/or alpha(1)-adrenoceptors through central and/or peripheral mechanisms. 2. In the present study, we tested the hypothesis that the baroreflex sensitivity (BRS)-enhancing effects of ketanserin are mediated by central 5-HT(2A) receptors in spontaneously hypertensive rats (SHR). 3. Using a conjugate of a monoclonal antibody to the serotonin reuptake transporter (SERT) and the toxin saporin (anti-SERT-SAP), which specifically eliminates the neurons that express SERT, the effects of ketanserin (0.3 and 3.0 mg/kg, i.g.) on BRS, blood pressure (BP), heart period (HP) and blood pressure variability (BPV) were compared between conscious intact SHR and SHR pretreated with anti-SERT-SAP. 4. Immunochemistry showed that, 2 weeks after intracerebroventricular injection of the toxin, 5-HT expression was strikingly attenuated in the brain, whereas values of BRS, BPV and BP were similar to those in the sham group. In intact SHR, 0.3 mg/kg ketanserin significantly improved BRS (191% control) and reduced BPV without affecting BP; at 3.0 mg/kg, ketanserin significantly increased BRS (197% control) and decreased BPV and BP. In toxin-pretreated SHR, only the high dose of ketanserin improved BRS (132% control), neither of the ketanserin doses reduced BPV, but both significantly decreased BP. 5. We conclude that the BRS-enhancing effects of ketanserin are mediated largely by central 5-HT(2A) receptors, whereas the antihypertensive effect of ketanserin persists even after destruction of serotonergic neurons in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600544     DOI: 10.1111/j.1440-1681.2007.04626.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

1.  Environment Influencing Serotonin Syndrome Induced by Ecstasy Abuse.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan
Journal:  Ann Forensic Res Anal       Date:  2017-03-07

2.  5-HT2A receptors are concentrated in regions of the human infant medulla involved in respiratory and autonomic control.

Authors:  David S Paterson; Ryan Darnall
Journal:  Auton Neurosci       Date:  2009-02-12       Impact factor: 3.145

Review 3.  Serotonin: a different player in hypertension-associated thrombosis.

Authors:  Mony Fraer; Fusun Kilic
Journal:  Hypertension       Date:  2015-03-09       Impact factor: 10.190

Review 4.  Serotonin gene variants are unlikely to play a significant role in the pathogenesis of the sudden infant death syndrome.

Authors:  David S Paterson
Journal:  Respir Physiol Neurobiol       Date:  2013-07-10       Impact factor: 1.931

5.  Effects of allisartan, a new AT(1) receptor blocker, on blood pressure and end-organ damage in hypertensive animals.

Authors:  Ming-yue Wu; Xiu-juan Ma; Chu Yang; Xia Tao; Ai-jun Liu; Ding-feng Su; Jian-guo Liu
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

6.  Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function.

Authors:  Jian-guang Yu; En-hui Zhang; Ai-jun Liu; Jian-guo Liu; Guo-jun Cai; Ding-feng Su
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

7.  Blood pressure reduction combining baroreflex restoration for stroke prevention in hypertension in rats.

Authors:  Shu-Wei Song; Ai-Jun Liu; Chong Bai; Bei-Lin Su; Xiu-Juan Ma; Fu-Ming Shen; Jun-Li Duan; Ding-Feng Su
Journal:  Front Pharmacol       Date:  2010-07-29       Impact factor: 5.810

8.  Quipazine Elicits Swallowing in the Arterially Perfused Rat Preparation: A Role for Medullary Raphe Nuclei?

Authors:  Victor Bergé-Laval; Christian Gestreau
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.